Investor Relations

Current Press Releases

Arch Biopartners Adds Farris Smith as a Strategic Advisor

October 05, 2022 07:20 ET | Source: Arch Biopartners TORONTO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of innovative technologies and novel therapeutics targeting organ inflammation, welcomed Mr. Farris Smith of Novo Nordisk Canada Inc as a Strategic Advisor for general corporate activity and business development of the Company’s drug candidates.
Mr. Farris Smith started his career with AP Moller in 2001 and joined Novo Nordisk in 2003 as ...
Full Release

Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials

August 05, 2022 07:30 ET | Source: Arch Biopartners TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company targeting acute organ inflammation with novel therapeutics, announced today that the Company has added Dr. David Luke as a Strategic Advisor for the clinical trial development of the Company’s drug candidates. Dr. Luke previously held a variety of positions in the pharma industry, including approximately twenty years at Pfizer Inc, where he was a Senior Medical Director, ...
Full Release

Arch Biopartners named to the 2022 TMX Venture 50 List of Top Performing TSX Venture Exchange Companies.

TORONTO, Feb. 24, 2022  — Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today that it has been named to the 2022 TMX Venture 50 List of Top Performing TSX Venture Exchange Companies as one of the top 10 companies in the category “Clean Technology and Life Sciences”.  Februrary 24, 2022 Arch Biopartners CEO, Richard Muruve interview with TMX Markets "We are honoured today to shine ...
Full Release
Contact Arch Biopartners
Stay connected!

Subscribe for email updates

Get email alerts when news is published
Please check the options for Investor News and Science Updates to receive additional information about events and publications

Press Release Archives